Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors
NCT05137275Phase 1Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2021
- Primary completion
- Apr 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-5T4 CAR-raNK cells in solid tumor, sponsored by Shanghai East Hospital. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events at 90 days and 5 more. Status: unknown.
02
Drugs
anti-5T4 CAR-raNK cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05137275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137275.